Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Portugal / NCT06758817
Recruiting Not applicable

The Triad of Nutrition, Intestinal Microbiota and Rheumatoid Arthritis (TASTY)

NCT06758817 · tracked via the Priya Life Science Portugal tracker
Sponsor
Lisbon Academic Medical Center - Centro Académico de Medicina de Lisboa
Phase
Not applicable
Started
2023-01-02
Last updated
2025-01-06

Condition(s) studied

Diet Interventions

Investigational drug(s) / intervention(s)

MedDiet+ interventionGeneral dietary recommendations

MedDiet+ intervention: Study arm will consume a Mediterranean like style diet enriched in fermented foods for 12 weeks

General dietary recommendations: Study arm will be given general healthy eating advice at baseline.

Study summary

The main goal of this trial is to investigate whether a dietary intervention based on a typical Mediterranean Diet enriched with fermented foods (MedDiet+) can impact gut microbiota and RA-related outcomes.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * RA patients (ACR/EULAR2010 criteria) * Age \>18-years * Disease duration \>1-year * Active disease (DAS28 \> 2.6units) * On stable medication for 12 weeks * Low/medium MedDiet adherence (PREDIMED\<10) * Willing to comply with study protocol Exclusion Criteria: * Prednisolone dose ≥ 7.5 mg/day * Antibiotic therapy 4-weeks prior to baseline * Persistent use of NSAID's * Inflammatory or irritable bowel disease * Celiac disease * Chronic diarrhea * Diabetes * Other immune-mediated inflammatory diseases besides RA * Major organ dysfunction * Cancer diagnosed in the last five years * Health conditions which may difficult participation (cognitive impairment/psychiatric disease) * Pregnant or lactating individuals

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Unidade Local de Saude de Santa Maria Lisbon Portugal Recruiting
Faculdade Medicina de Lisboa Lisbon Portugal Recruiting

More Lisbon Academic Medical Center - Centro Académico de Medicina de Lisboa trials in Portugal

Radiographic Head and Neck Positional Changes in Response to Usage of Low-powered Prismatic Lenses Recruiting
Cardiac Remodelling Following Endovascular Repair of the Aorta Recruiting
UP STUDY - Decipher Persistent Critical Illness Through in Deep Clinical Phenotyping. Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06758817 on ClinicalTrials.gov ↗ ← All trials in Portugal